INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC
ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) complied with federal securities laws. On November 3, 2025, uniQure disclosed it had a pre-Biologics License Application (“BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) and that based on the meeting, “uniQure believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.” Following this news, the price of the Company’s stock dropped.
If you purchased uniQure stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/uniqure/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
